Helio Health
Coming February 10

Earlier Detection Of Cancer Means More Effective Treatment

Date & Time

February 10, 3:00 PM ET / 12:00 PM PT
Webinar: Details provided upon RSVP approval

About the Event

Helio Health is a biotechnology company dedicated to saving lives by detecting cancer early. Their liquid biopsy test is a first-in-market blood test that uses methylation markers, A.I. and machine learning to analyze DNA and detect the presence of cancer at a very early stage. The company has just released a multi-analyte blood test for liver cancer via their partner, Fulgent Genetics (NASDAQ: FLGT), that has a 75% sensitivity rate versus 25% for the current standard of care when the cancer is still very early.

Their diagnostic platform includes significant I.P. around the conversion of samples, algorithms, and more than 3,000 methylation markers for over 20 cancers. The company is using the platform to develop tests for colon and breast cancer, with others to be developed in the near future.

Join this webinar to hear from Helio Health CEO, Justin Li as he and his team share the latest developments that have the company poised for explosive growth as their testing platform gets rolled out nationwide.


Share on facebook
Share on twitter
Share on linkedin

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.